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G protein–coupled receptors represent the largest
superfamily of receptors in the human genome.
They are intricate sensors and transducers and are
fundamental to physiology and disease. Drugs
that target these receptors have therapeutic utility
and potential and include beta-blockers and block-
ers of type 1 angiotensin (AT1) receptors. Tradition-
ally, G protein–coupled receptors were thought to
act as monomers, in which one ligand binds and
activates a single receptor–G protein complex. New-
er evidence,1 however, points to the existence of
higher-order complexes (dimers or oligomers) with
altered pharmacology, responsiveness, or both.2,3
A recent report by AbdAlla and colleagues4 not only
underscores the critical nature of a dimer made up
of AT1 receptors, but also describes a pivotal event
in the formation of the dimer (Fig. 1).
Blood pressure is governed in part by the angi-
otensin-converting enzyme (ACE), which gener-
ates the peptide hormone angiotensin II in blood
and tissues. In turn, angiotensin II acts through the
AT1 receptor to regulate arterial blood pressure and
water–salt balance. Overactivity of the angioten-
sin II–AT1 axis leads to hypertension; cardiac, renal,
and vascular remodeling; and substantial morbidi-
ty and mortality from conditions such as myocar-
dial infarction, congestive heart failure, stroke, and
type 2 diabetes. ACE inhibitors and AT1-receptor
blockers alleviate these conditions.
The AT1 receptor is a G protein–coupled recep-
tor that activates the Gq/11 protein and initiates a
plethora of signals that affect cell function, includ-
ing the liberation of inositol phosphates that mo-
bilize intracellular calcium. Because this is one of
the most comprehensively studied homeostatic sys-
tems, some might argue that further research into
angiotensin II and AT1 receptors could yield only
incremental advances. Thus, the study by AbdAlla
et al. is remarkable in that it sheds light on another
twist in the repertoire of the actions of angioten-
sin II, as well as on another mechanism of dimer-
ization.
AbdAlla et al.4 first confirmed that monocytes
from patients with essential hypertension were
activated in an angiotensin II–dependent manner,
responding to the peptide with enhanced cytokine
release and adhesion to endothelial cells. The source
of angiotensin II seemed likely to be the monocytes
themselves, because their ACE activity was higher
in patients with hypertension than in normoten-
sive subjects. Although monocytes isolated from
normotensive subjects and patients with hyper-
tension expressed similar levels of AT1 receptors,
immunoblotting of monocyte membranes with an
AT1-receptor antibody demonstrated markedly dif-
ferent patterns of migration of the receptor protein
on sodium dodecyl sulfate–polyacrylamide-gel elec-
Figure 1 (facing page). Monocytic Activation Leading 
to Atherosclerosis.
As reported by AbdAlla et al.,4 monocytes from patients 
with hypertension and dyslipidemic mice had increased 
adherence to the endothelium of blood vessels in an an-
giotensin II (AngII)–dependent manner. These mono-
cytes are the precursors of subendothelial macrophages 
that acquire and store cholesterol and establish the in-
flammatory characteristics and complex lesions of ath-
erosclerosis. The increased adherence is dependent on 
two properties of the activated monocytes: an increased 
capacity to generate angiotensin II by means of the angi-
otensin-converting enzyme (ACE) and — as shown by 
AbdAlla et al.4 — increased activity of activated factor 
XIII (factor XIIIa) transglutaminase; transglutaminase 
catalyzes the cross-linking of monomeric AT1 receptors 
into covalent dimers with enhanced signaling capacity. 
The target of factor XIIIa transglutaminase is glutamine 
at position 315 (Gln315) in the carboxy terminus of the 
359-amino-acid AT1 receptor and presumably one or 
more of the many available lysine residues present in the 
intracellular domains of an adjacent receptor.
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trophoresis. In normotensive subjects, the AT1
receptor resolved predominantly as a monomer,
whereas in patients with hypertension, the receptor
appeared to be in a dimeric form, which was stable
under the reducing and denaturing conditions used.
This finding suggested that the dimerized recep-
tors were covalently bound.
The researchers then found that the levels and
activity of activated factor XIII (factor XIIIa) trans-
glutaminase were higher in the monocytes from
hypertensive patients than in those from normo-
tensive subjects. Transglutaminases are a family of
calcium-dependent enzymes that catalyze the cross-
linking of proteins, including membrane proteins,
through the amino acids glutamine and lysine.5
Factor XIIIa is best known for cross-linking the fi-
brin network during blood coagulation. However,
factor XIIIa appears to be acting within monocytes.
As might be expected, increasing the levels of intra-
cellular calcium by means of the calcium ionophore
ionomycin stimulated the transglutaminase activity
of factor XIIIa in monocytes. Remarkably, AbdAlla
et al. found that treatment of monocytes with both
angiotensin II and ionomycin resulted in the for-
mation of covalent AT1-receptor dimers. Site-direct-
ed mutagenesis established that glutamine at po-
sition 315 (Gln315) within the carboxy terminus of
the AT1 receptor is the probable target of factor
XIIIa transglutaminase activity and cross-linking.
Interestingly, dimerized wild-type AT1 receptor
(but not the Gln315 mutant) was characterized by
increases in coupling to Gq/11, generation of ino-
sitol phosphate, and mobilization of calcium, as
compared with the monomeric form, indicating
that dimeric AT1 receptors are hyperactive.
Multiple lines of evidence indicate that the trans-
glutaminase activity of factor XIIIa is responsible for
covalently dimerizing AT1 receptors. First, dimers
do not form on monocytes from patients with a
congenital deficiency of factor XIIIa. Second, factor
XIIIa–dependent dimerization could be induced in
cells made to express the AT1 receptor and factor
XIIIa but not in cells expressing a catalytically inac-
tive form of factor XIII. Third, after three months of
treatment with ACE inhibitors, hypertensive pa-
tients had primarily monomeric AT1 receptors, de-
creased levels of factor XIIIa, and diminished mono-
cyte adhesion. Finally, in mice with an inactivated
gene for apolipoprotein E — an established angio-
tensin II–dependent model of hypercholesterole-
mic atherosclerosis — inhibition of ACE or factor
XIIIa eliminated AT1 receptor dimers, halted mono-
cyte infiltration, and abolished the propensity for
vascular lesions.
What makes the study by AbdAlla et al. provoc-
ative? First, transglutaminase-mediated cross-link-
ing of G protein–coupled receptors is a novel find-
ing and represents a paradigm shift from theories
of dimerization that are based on disulfide bridg-
ing or interactions between transmembrane do-
mains.1 As with any major advance, healthy skep-
ticism is warranted until this observation has been
replicated. Nevertheless, the apparent dimeriza-
tion-selective activation and subsequent adhesion
of monocytes expands the astounding array of ac-
tions ascribed to angiotensin II and AT1 receptors
with respect to cardiovascular dysfunction. Given
that the monocyte transglutaminase activity of fac-
tor XIIIa is intracellular and therefore sequestered
from thrombin-dependent clot formation in blood,
this discovery may provide the impetus for the de-
velopment of monocyte-selective therapies in the
form of agents that target factor XIIIa. Finally, de-
termining why AT1-receptor homodimers are sub-
stantially more active than AT1-receptor monomers
may provide new avenues for designing drugs that
target G protein–coupled receptor function.
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